Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneur
Latest Ratings for ALNY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2017 | BMO Capital | Initiates Coverage On | Outperform | |
| Mar 2017 | UBS | Initiates Coverage On | Neutral | |
| Feb 2017 | Ladenburg Thalmann | Initiates Coverage On | Buy |
View More Analyst Ratings for ALNY
View the Latest Analyst Ratings
May 15, 2017 at 09:26PM
from Shanthi Rexaline
No comments:
Post a Comment